Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance© Stocktwits GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 ...

Vaccine manufacturer GSK plans to invest $800 million in its Lancaster County facility, creating 200 new jobs and expanding its manufacturing and R&D capabilities.

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...